These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Tardive dyskinesia. Casey DE West J Med; 1990 Nov; 153(5):535-41. PubMed ID: 1979705 [TBL] [Abstract][Full Text] [Related]
43. Tardive dyskinesia in the aged. Duration of treatment relationships. Toenniessen LM; Casey DE; McFarland BH Arch Gen Psychiatry; 1985 Mar; 42(3):278-84. PubMed ID: 2858189 [TBL] [Abstract][Full Text] [Related]
44. Duration of neuroleptic treatment and prevalence of tardive dyskinesia in late life. Sweet RA; Mulsant BH; Gupta B; Rifai AH; Pasternak RE; McEachran A; Zubenko GS Arch Gen Psychiatry; 1995 Jun; 52(6):478-86. PubMed ID: 7771918 [TBL] [Abstract][Full Text] [Related]
45. Disclosure of tardive dyskinesia: effect of written policy on risk disclosure. Kennedy NJ; Sanborn JS Psychopharmacol Bull; 1992; 28(1):93-100. PubMed ID: 1351688 [TBL] [Abstract][Full Text] [Related]
46. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Jeste DV; Caligiuri MP; Paulsen JS; Heaton RK; Lacro JP; Harris MJ; Bailey A; Fell RL; McAdams LA Arch Gen Psychiatry; 1995 Sep; 52(9):756-65. PubMed ID: 7654127 [TBL] [Abstract][Full Text] [Related]
47. Not all that moves is tardive dyskinesia. Khot V; Wyatt RJ Am J Psychiatry; 1991 May; 148(5):661-6. PubMed ID: 1673323 [TBL] [Abstract][Full Text] [Related]
48. Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study. Sachdev P Aust N Z J Psychiatry; 2004 Jun; 38(6):445-9. PubMed ID: 15209837 [TBL] [Abstract][Full Text] [Related]
49. Intermittent neuroleptic therapy and tardive dyskinesia: a literature review. Goldman MB; Luchins DJ Hosp Community Psychiatry; 1984 Dec; 35(12):1215-9. PubMed ID: 6150891 [TBL] [Abstract][Full Text] [Related]
50. Micro-effects of language on risk perception in drug prescribing behavior. Bursztajn HJ; Chanowitz B; Gutheil TG; Hamm RM Bull Am Acad Psychiatry Law; 1992; 20(1):59-66. PubMed ID: 1349499 [TBL] [Abstract][Full Text] [Related]
51. Tardive dyskinesia in northern Israel: preliminary study. Schwartz M; Silver H; Tal I; Sharf B Eur Neurol; 1993; 33(3):264-6. PubMed ID: 8096816 [TBL] [Abstract][Full Text] [Related]
52. Case study: childhood-onset tardive dyskinesia versus choreoacanthocytosis. Borchardt CM; Jensen C; Dean CE; Tori J J Am Acad Child Adolesc Psychiatry; 2000 Aug; 39(8):1055-8. PubMed ID: 10939235 [TBL] [Abstract][Full Text] [Related]
53. Is tardive dyskinesia a unique disorder? Marsden CD Psychopharmacology Suppl; 1985; 2():64-71. PubMed ID: 2860661 [TBL] [Abstract][Full Text] [Related]
54. [Tardive dyskinesia in long-term treatment with neuroleptics--review of the literature and personal experience with its therapy]. Cesková E; Svestka J; Peska I; Náhunek K; Rysánek R Cesk Psychiatr; 1990 Aug; 86(4):269-74. PubMed ID: 1978805 [No Abstract] [Full Text] [Related]
55. A comparison of severe tardive dystonia and severe tardive dyskinesia. Yassa R; Nair V; Iskandar H Acta Psychiatr Scand; 1989 Aug; 80(2):155-9. PubMed ID: 2572146 [TBL] [Abstract][Full Text] [Related]
57. Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents. Gualtieri CT; Quade D; Hicks RE; Mayo JP; Schroeder SR Am J Psychiatry; 1984 Jan; 141(1):20-3. PubMed ID: 6140865 [TBL] [Abstract][Full Text] [Related]
58. New findings on tardive dyskinesia in a community sample. O'Hara P; Brugha TS; Lesage A; Wing J Psychol Med; 1993 May; 23(2):453-65. PubMed ID: 8101384 [TBL] [Abstract][Full Text] [Related]
59. Management of tardive dyskinesia: current update. Simpson GM; Pi EH; Sramek JJ Drugs; 1982 May; 23(5):381-93. PubMed ID: 7047137 [TBL] [Abstract][Full Text] [Related]